Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01964404 · ClinicalTrials.gov registry record · Phase 1
Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
A Phase 1 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 263
- Enrollment target
NCT01964404 is a Phase 1 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 263 participants.
The verdict
NCT01964404, a Phase 1 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 263 participants
- Enrollment target
Study Summary
In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients with schizophrenia and co-occurring cannabis use disorder, will in fact ameliorate the brain reward circuit dysregulation in these patients and, thereby, provide evidence in support of the role of cannabis as a "self-medication" agent for them.
Interventions
- DRUG Placebo
- DRUG Dronabinol
- DRUG Marijuana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2014-07 |
| Est. Completion | 2021-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01964404
The ClinicalTrials.gov registry entry for NCT01964404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01964404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01964404 about?
NCT01964404 is a clinical study titled "Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?". In this translational research proposal, based on our formulation, we seek to confirm and expand upon data obtained in our pilot study suggesting that cannabis and the cannabinoid agonist dronabinol, given in low dose to patients with schizophrenia and co-occurring cannabis use disorder, will in fac...
What is the current status of trial NCT01964404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 263 participants. The study started on 2014-07. Estimated completion is 2021-09-18.
What interventions are being tested in trial NCT01964404?
The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG), Marijuana (DRUG).
Who is sponsoring clinical trial NCT01964404?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.